Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic Results

• Published in: Clinical cancer research Vol. 15; no. 23; pp. 7375 - 7380
• Main Authors: LUBAROFF, David M, KONETY, Badrinath R, WILLIAMS, Richard D, LINK, Brian, GERSTBREIN, Jack, MADSEN, Tammy, SHANNON, Mary, HOWARD, Jeanne, PAISLEY, Jennifer, BOEGLIN, Diana, RATLIFF, Timothy L
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.12.2009
• Subjects: Adenoviridae - genetics; Aged; Aged, 80 and over; Antineoplastic agents; Biological and medical sciences; Cancer Vaccines - therapeutic use; Collagen - chemistry; Gelatin Sponge, Absorbable - chemistry; Gynecology. Andrology. Obstetrics; Hormones - metabolism; Humans; immunotherapy; Male; Male genital diseases; Medical sciences; Middle Aged; Neoplasm Metastasis; Nephrology. Urinary tract diseases; Pharmacology. Drug treatments; prostate cancer; Prostate-Specific Antigen - genetics; Prostatic Neoplasms - therapy; T-Lymphocytes - metabolism; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; vaccine; Human; Urinary system disease; Adenoviridae; Prostate disease; Toxicity; Tumoral marker; Vaccine; Malignant tumor; Virus; Prostate specific antigen; Treatment; Phase I trial; Safety; Gene therapy; Male genital diseases; Prostate cancer; Cancer

Purpose: We performed a phase I clinical trial of adenovirus/prostate-specific antigen (PSA) vaccine in men with measurable metastatic hormone-refractory disease. Experimental Design: Men with measurable metastatic disease received one vaccine injection. Toxicity, immune responses, changes in PSA do...